Primary care use of FRAX®: Absolute fracture risk assessment in postmenopausal women and older men

Postgraduate Medicine

Volumn 122, Issue 1, 2010, Pages 82-90

  Siris, Ethel S ^a   Baim, Sanford ^b,c   Nattiv, Aurelia ^d  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c University of Colorado Health Sciences Center   (United States)

^d Santa Monica UCLA Medical Center   (United States)

Author keywords

Clinical risk factors; Fracture; FRAX ; Osteopenia; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; IBANDRONIC ACID; RALOXIFENE; ZOLEDRONIC ACID;

ADULT; AGED; BONE DENSITY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG INDICATION; ELDERLY CARE; FEMALE; FRAGILITY FRACTURE; HEALTH CARE FACILITY; HIP FRACTURE; HUMAN; MALE; MENOPAUSAL SYNDROME; PRIMARY MEDICAL CARE; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; WORLD HEALTH ORGANIZATION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALGORITHMS; BONE DENSITY; BONE DISEASES, METABOLIC; FEMALE; FRACTURES, BONE; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PRIMARY HEALTH CARE; RISK ASSESSMENT; RISK FACTORS;

EID: 76249120071     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.01.2102     Document Type: Review

References (48)

1. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis, http://www.nof.org/professionals/NOF-Clinicians- Guide.pdf. Accessed October 4, 2009.
2. Cole ZA, Dennison EM, Cooper C. Osteoporosis epidemiology update. Curr Rheumatol Rep. 2008;10(2):92-96.
3. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, et al; National Osteoporosis Foundation Guide Committee. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int. 2008;19(4):437-447.
4. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785-795.
5. World Health Organization. Summary Meeting Report. Brussels, Belgium: World Health Organization, Scientific Group on the Assessment of Osteoporosis at Primary Care Level; 2004.
6. Looker AC, Orwoll ES, Johnston CC Jr, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12(11): 1761-1768.
7. Sins ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164(10):1108-1112.
8. Khosla S, Melton LJ 3rd. Clinical practice. Osteopenia. N Engl J Med. 2007;356(22):2293-2300.
9. Wainwnight SA, Marshall LM, Ensrud KE, et al; Study of Osteoporotic Fractures Research Group. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab. 2005;90(5):2787-2793.
10. Pasco JA, Seeman E, Henry MJ, Merriman EN, Nicholson GC, Kotowicz MA. The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int. 2006;17(9): 1404-1409.
11. Sornay-Rendu E, Munoz F, Gamero P, Duboeuf F, Delmas PD. Identification of osteopenic women at high risk of fracture: The OFELY study. J Bone Miner Res. 2005;20(10):1813-1819.
12. Sanders KM, Nicholson GC, Watts JJ, et al. Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone. 2006;38(5):694-700.
13. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385-397.
14. Kanis JA, Oden A, Johansson H, Borgström F, Ström O, McCloskey E. FRAX and its applications to clinical practice. Bone. 2009:44(5): 734-743.
15. Chen YT, Miller PD, Barrett-Conner E, Weiss TW, Sajjan SG, Siris ES. An approach for identifying postmenopausal women age 50-64 years at increased short-term risk for osteoporotic fracture. Osteoporos Int. 2007:18(9):1287-1296.
16. Black DM, Steinbuch M, Palermo L, et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos int. 2001:12(7):519-528.
17. Kanis JA. FRAX WHO fracture risk assessment tool. http://www.shef.ac.uk/ FRAX/index.htm. Accessed June 18, 2009.
18. Kanis JA. FRAX WHO fracture risk assessment tool: frequently asked questions. http://www.shef.ac.uk/FRAX/faq.htm. Accessed June 18, 2009.
19. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35(2):375-382.
20. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int. 2005;16(6):581-589.
21. Siris ES, Brenneman SK, Barrett-Connor E, et al. The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA), Osteoporos Int. 2006:17(4): 565-574.
22. Cummings SR, Cawthon PM, Ensrud KE, Cauley JA, Fink HA, Orwoll ES; Osteoporotic Fractures in Men (MrOS) Research Groups; Study of Osteoporotic Fractures Research Groups. BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res. 2006;21(10):1550-1556.
23. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18(8): 1033-1046.
24. Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int. 2005:16(2):155-162.
25. Kanis JA, Johansson H, Johnell O, et al, Alcohol intake as a risk factor for fracture. Osteoporos Int. 2005;16(7):737-742.
26. Watts NB, Ettinger B, Leboff MS. FRAX facts. J Bone Miner Res. 2009;24(6):975-979.
27. Kanis JA, Black D, Cooper C, et al; International Osteoporosis Foundation; National Osteoporosis Foundation. A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int. 2002:13(7):527-536.
28. Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA. Lifetime risk of hip fractures is underestimated. Osteoporos Int. 1998:8(6): 599-603.
29. Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int. 2008:19(4):449-458.
30. Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998;8(5):468-489.
31. National Osteoporosis Foundation. FRAX® implementation guide released to DXA manufacturers. http://www.nof.org/news/pressreleases/2009O922-FRAX- Implementation-Guide.htm. Accessed December 1, 2009.
32. Kanis J. FRAX Release Notes. September 7; http://shef.ac.uk/FRAX/FRAX- Release-Notes.pdf. Accessed October 4, 2009.
33. Ettinger B, Black DM, Dawson-Hughes B, Pressman AR, Melton LJ 3rd. Updated fracture incidence rates for the US version of FRAX®. Osteoporos Int. 2010:21(1):25-33.
34. Kanis JA, Johansson H, Oden A, et al. A family history of fracture and fracture risk: a meta-analysis. Bone. 2004:35(5):1029-1037.
35. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19(6): 893-899.
36. Lewiecki EM, Watts NB. New guidelines for the prevention and treatment of osteoporosis. South Med J. 2009:102(2):175-179.
37. Donaldson MG, Palermo L, Schousboe JT, Ensrud KE, Hochberg MC, Cummings SR. FRAX and risk of vertebral fractures: The Fracture Intervention Trial (FIT). J Bone Miner Res. 2009:24(11):1793-1799.
38. Dargent-Molina P, Favier F, Grandjean H, et al. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet. 1996; 348(9021):145-149.
39. Dargent-Molina P, Schott AM, Hans D, et al. Separate and combined value of bone mass and gait speed measurements in screening for hip fracture risk: results from the EPIDOS study. Epidémiologic de l'Ostéoporose. Osteoporos Int. 1999;9(2):188-192.
40. Jarvinen TL, Sievanen H, Khan KM, Heinonen A, Kannus P. Shifting the focus in fracture prevention from osteoporosis to falls. B.M.J. 2008;336(7636):124-126.
41. Bayly J, Masud T. Preventing falls: Not at the expense of osteoporosis care. BMJ. 2008:336(7640):343.
42. Berry SD, Samelson EJ, Hannan MT, et al. Second hip fracture in older men and women: the Framingham Study. Arch Intern Med. 2007; 167(18):1971-1976.
43. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013-1022.
44. Donaldson MG, Cawthon PM, Lui LY, et al; Study of Osteoporotic Fractures. Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new U.S. National Osteoporosis Foundation Guidelines. J Bone Miner Res. 2009:24(4):675-680.
45. Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ 3rd. The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int. 2010;21(1):41-52.
46. McCloskey EV, Beneton M, Charlesworth D, et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res. 2007:22(1):135-141.
47. McCloskey EV, Johansson H, Oden A, et al. Ten-year fracture probability identifies women who will benefit from clodronate therapy - additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int. 2009:20(5):8 11-817.
48. Stroup J, Kane MP, Abu-Baker AM. Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm. 2008;65(6):532-539.